NCT05757336View on ClinicalTrials.gov

Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 22, 2022

Primary Completion Date

December 22, 2024

Study Completion Date

December 22, 2026

Conditions
Gallbladder CancerInitially Unresectablethe First Line Treatment
Interventions
DRUG

Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab

Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Lu Wang, MD, PhD

OTHER